GLP1R gene variant is associated with glycaemic response to treatment with DPP-4 inhibitors

被引：0
|
作者：
Javorsky, M. [1 ,2 ]
Gotthardova, I. [1 ]
Klimcakova, L. [3 ]
Kvapil, M. [4 ,5 ]
Schroner, Z. [1 ]
Doubravova, P. [4 ]
Zidzik, J. [3 ]
Gal'a, I. [1 ]
Dravecka, I. [6 ]
Tkac, I. [1 ]
机构：
[1] Safarik Univ, Sch Med, Dept Med 4, Kosice, Slovakia
[2] Pasteur Teaching Hosp, Kosice, Slovakia
[3] Safarik Univ, Sch Med, Inst Med Biol & Genet, Kosice, Slovakia
[4] Fac Med 2, Prague, Czech Republic
[5] Fac Hosp Motol, Prague, Czech Republic
[6] Safarik Univ, Sch Med, Dept Med 1, Kosice, Slovakia
来源：
DIABETOLOGIA | 2016年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
783
引用
收藏
页码：S373 / S374
页数：2
相关论文
共 50 条
  • [1] A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes
    Han, Eugene
    Park, Hye Sun
    Kwon, Obin
    Choe, Eun Yeong
    Wang, Hye Jin
    Lee, Yong-ho
    Lee, Sang-Hak
    Kim, Chul Hoon
    Kim, Lee-Kyung
    Kwak, Soo Heon
    Park, Kyong Soo
    Kim, Chul Sik
    Kang, Eun Seok
    MEDICINE, 2016, 95 (44)
  • [2] A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins
    Javorsky, M.
    Gotthardova, I.
    Klimcakova, L.
    Kvapil, M.
    Zidzik, J.
    Schroner, Z.
    Doubravova, P.
    Gala, I.
    Dravecka, I.
    Tkac, I.
    DIABETES OBESITY & METABOLISM, 2016, 18 (09): : 941 - 944
  • [3] KCNQ1 gene polymorphism is associated with glycaemic response to treatment with DPP-4 inhibitors
    Gotthardova, Ivana
    Javorsky, Martin
    Klimcakova, Lucia
    Kvapil, Milan
    Schroner, Zbynek
    Kozarova, Miriam
    Malachovska, Zuzana
    Urgeova, Anna
    Zidzik, Jozef
    Tkac, Ivan
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2017, 130 : 142 - 147
  • [4] GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes
    Ahrén, B
    Schmitz, O
    HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) : 867 - 876
  • [5] A Polymorphism in GLP-1 Receptor Gene Is Associated with DPP-4 Inhibitor Response in Patients with Type 2 Diabetes
    Han, Eugene
    Park, Hye Sun
    Kwon, Obin
    Kim, Gyuri
    Kim, So Ra
    Kwak, Soo-Heon
    Lee, Ji-Yeon
    Choe, Eun Yeong
    Wang, Hye Jin
    Lee, Yong-Ho
    Kim, Chul Hoon
    Lee, Sang-Hak
    Lee, Byung Wan
    Cha, Bong Soo
    Kang, Eun Seok
    DIABETES, 2016, 65 : A422 - A422
  • [6] DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
    Michael Razavi
    Ying-Ying Wei
    Xiao-Quan Rao
    Ji-Xin Zhong
    Military Medical Research, 9
  • [7] DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
    Michael Razavi
    Ying-Ying Wei
    Xiao-Quan Rao
    Ji-Xin Zhong
    Military Medical Research, 2023, (02) : 227 - 241
  • [8] DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
    Razavi, Michael
    Wei, Ying-Ying
    Rao, Xiao-Quan
    Zhong, Ji-Xin
    MILITARY MEDICAL RESEARCH, 2022, 9 (01)
  • [9] Meta analysis of the efficacy of GLP-1R agonists and DPP-4 inhibitors for treatment of type 2 diabetes mellitus
    Aroda, V. R.
    Henry, R. R.
    Han, J.
    Huang, W.
    Peters, Y.
    Darsow, T.
    Hoogwerf, B. J.
    DIABETOLOGIA, 2010, 53
  • [10] GLP1R variant is associated with response to exenatide in overweight Chinese Type 2 diabetes patients
    Yu, Mingjun
    Wang, Kaiyu
    Liu, Haiming
    Cao, Rui
    PHARMACOGENOMICS, 2019, 20 (04) : 273 - 278
12345